ICE Bioscience develops and validates in vitro drug-resistant cancer cell line models relevant to ADCs and cytotoxic payloads. Our portfolio includes resistant sublines generated by drug-induced selection as well as engineered models supporting transporter- or target-driven resistance hypotheses.

Resistance Index (RI) represents the fold increase in IC50 for the resistant subline relative to the parental line. STR indicates cell line authentication by short tandem repeat profiling. RNA-seq and whole-exome sequencing (WES) are available as optional profiling modules where noted.

Drug-induced selection models

1. Resistant sublines established through continuous or stepwise exposure to an ADC or payload, followed by RI assessment, stability validation, and STR authentication. Optional add-ons include transcriptomics (RNA-seq) and/or WES to support mechanism exploration and hypothesis refinement.

2. Genome editing and mechanism-driven models Engineered resistance models built to test defined hypotheses, including ABC transporter overexpression (ABCB1, ABCG2) and target-altering variants such as TOP1 mutation models, supporting efflux- and target-driven resistance scenarios.